Nine cases of lymphoblastic lymphoma and eight cases of small, noncleaved undifferentiated non-Burkitt's lymphoma were studied. All cases were stained with monoclonal antibodies, directed to the leukocyte common antigen (LCA), B- and T-cell markers as well as Calla. Small noncleaved, undifferentiated non-Burkitt's lymphomas were LCA positive and expressed one or more B-cell markers. Three cases of lymphoblastic lymphoma were LCA positive and showed reactivity with antibodies OKT4, OKT6 and OKT8. The six remaining cases of lymphoblastic lymphoma were LCA negative, except for only one case that was weakly LCA positive using more sensitive detection methods. Two of the LCA negative cases expressed Calla, and four cases did not show any reactivity with the monoclonal antibodies used. In all LCA negative cases, small residual non-neoplastic nodules representing remnants of lymphoid follicles, could be detected. Since five out of nine cases of lymphoblastic lymphoma were LCA negative, lack of staining for LCA does not preclude the diagnosis of lymphoma.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1002/path.1711510404 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Successful desensitization of donor-specific antibodies in a single cord blood transplant recipient.
Hematology
December 2025
Cellular Therapy & Transplantation Program, Hopital Maisonneuve-Rosemont, Universite de Montreal, Montreal, Quebec, Canada.
Umbilical cord blood (UCB) represents a valuable graft source in the absence of a human leukocyte antigen (HLA)-matched donor for hematopoietic cell transplantation (HCT). Donor-specific anti-HLA antibodies (DSAs), targeting grafts with mismatched HLA antigens, pose a significant obstacle by increasing the risk of primary graft failure, delayed engraftment, and decreased survival. Existing literature on HLA desensitization has primarily focused on haploidentical transplants, and there is a lack of experience regarding the optimal strategy in UCB transplantation.
View Article and Find Full Text PDFUtility of Daratumumab as Bridging Therapy in De Novo T-Cell Acute Lymphoblastic Lymphoma.
Pediatr Blood Cancer
January 2025
Department of Clinical Haematology, Oncology, Blood and Marrow Transplantation, Perth Children's Hospital, Perth, Western Australia, Australia.
[Pseudohiponatremia secondary to hypertriglyceridemia during the treatment of lymphoblastic lymphoma with corticoids and L-asparaginase].
Andes Pediatr
August 2024
Hemato-Oncología Infantil, Universidad Austral de Chile, Valdivia, Chile.
Unlabelled: L-asparaginase (L-asp) is an antineoplastic drug used in Leukemia and Lymphoma treatment protocols. Alterations in lipid metabolism have been reported in 10-50% of children treated with L-Asp.
Objective: To report an unusual complication of lipid metabolism associated with the use of L-Asp.
Genomic and Clinicopathological Characterization of CRLF2-Rearranged Mixed Phenotype Acute Leukemia.
Pediatr Blood Cancer
January 2025
Departments of Pathology, University of Texas Southwestern Medical Center, Dallas, Texas, USA.
Rearrangements of cytokine receptor-like factor 2 gene (CRLF2) are present in ∼50% of B-lymphoblastic leukemia/lymphoma (B-ALL) with BCR::ABL1-like features. Herein, we report three patients with CRLF2-rearranged mixed phenotype acute leukemia (MPAL). All three cases were B/myeloid MPAL in young patients harboring P2RY8::CRLF2 or IGH::CRLF2 with additional genomic alterations in signaling (JAK and RAS) and cell cycle (CDKN2A/B) pathways, a genomic profile similar to that in BCR::ABL1-like B-ALL.
View Article and Find Full Text PDFClinical Characteristics, Risk Factors and Outcomes of Invasive Fungal Disease in Critically III Patients with Hematological Malignancy: A Retrospective Study.
Clin Lymphoma Myeloma Leuk
December 2024
Department of Intensive Care Medicine, the Affiliated Hospital of Guizhou Medical University, Guiyang, Guizhou, China. Electronic address:
Background: Invasive fungal disease (IFD) poses significant challenges for critically ill patients with hematological malignancies (HMs). However, there is limited research on the clinical characteristics, risk factors, and outcomes of IFD within this population.
Method: A retrospective study was conducted at a tertiary center in China.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!